NexPoint Life Sciences III DST Overview
NexPoint Life Sciences III DST is a Delaware Statutory Trust (DST) offering Class 1 beneficial interests in a single, mission-critical life-sciences asset. The Property, known as "11200 Hudson Road," is a 137,811-square-foot medical device research, development, and manufacturing facility built in 2021 on approximately 11.73 acres in Woodbury, Minnesota, within the Minneapolis-St. Paul-Bloomington MSA. As of December 31, 2023, the building was 100% leased to Kindeva, a global contract development and manufacturing organization (CDMO) specializing in drug-device combination products, which occupies the facility as its corporate headquarters and a majority of its manufacturing operations. Kindeva's lease carries a 15-year initial term that commenced in 2021 and runs through September 30, 2036, with three five-year extension options. Structured for accredited investors completing a Section 1031 exchange as well as those seeking passive real estate income, the Trust master-leases the entire Property to an affiliated Master Tenant under an "absolute net" master lease. The offering raises up to $30,661,253 of equity representing 100% ownership of the Trust, with a minimum purchase of $100,000 (a 0.326% interest, plus $102,083 of assumed debt). The Property was acquired at a $57,750,000 purchase price (appraised "as is" at $59,000,000 by BBG) and is capitalized with an assumed $31,300,000 non-recourse first-mortgage loan from Wings Financial Credit Union, yielding a loan-to-capitalization ratio of approximately 50.52%. The Sponsor is NexPoint, a Dallas-based alternative investment platform. The offering is designed for accredited 1031 exchangers who want passive, single-tenant net-lease income backed by a specialized, hard-to-replicate life-sciences building and who can accept illiquidity, leverage, and the absence of day-to-day control that the DST form requires.
Highlights
Location and market strength: The Property sits in Woodbury, Minnesota, a suburb within the Minneapolis-St. Paul-Bloomington MSA (the "Minneapolis MSA"), one of the more diversified and resilient metropolitan economies in the Upper Midwest. The Sponsor positions the asset within a broader life-sciences thesis: publicly traded life-science REITs have historically outperformed broader REIT indices over the past two decades, aided by roughly 300 basis points of capitalization-rate compression since 2010 as institutional demand for research and manufacturing space has grown. The submarket benefits from favorable demographics, a deep pool of scientific and manufacturing talent, and persistent supply-demand imbalance for specialized, purpose-built laboratory and production facilities. Because life-sciences tenants install costly, patented research and manufacturing infrastructure into their buildings, these assets tend to carry a high barrier to vacate, reinforcing the location's role as mission-critical space for the Tenant rather than commodity real estate that competes purely on rent.
Property quality and tenancy: 11200 Hudson Road is a modern, purpose-built facility completed in 2021, comprising approximately 137,811 rentable square feet on an 11.73-acre site with roughly 250 parking spaces, cast-in-place and pre-cast concrete tilt-up construction, and a one-story configuration with mezzanine. A BBG appraisal dated October 23, 2023 assigned an "as is" market value of $59,000,000, and a Property Condition Assessment identified no immediate repairs, with the Tenant responsible for repair and maintenance under its lease. The building is 100% occupied by Kindeva, a global CDMO and industry leader in combination drug delivery across pulmonary/nasal, injectable, and transdermal therapies, backed by Altaris Capital Partners and serving a global client base from nine facilities in the U.S. and U.K. The asset houses Kindeva's corporate headquarters and the bulk of its manufacturing, making it fundamental to the Tenant's business and giving the space real switching-cost "stickiness" beyond a typical single-tenant net lease.
Financing and capital structure: The Trust assumed a $31,300,000 first-mortgage loan from Wings Financial Credit Union with a 10-year term. The Loan is interest-only for the first 36 months; beginning in late 2029 the interest rate resets to the then-current three-year U.S. Treasury Constant Maturity yield plus 2.00%, subject to a floor of 4.25% and a cap of 6.25% (the PPM models a projected 2029 rate of 6.25%), and principal amortizes on an assumed 300-month (25-year) schedule beginning around December 2025. The financing is non-recourse to the Trust apart from standard non-recourse carve-outs, and beneficial owners are not required to sign personal guarantees or assume personal liability for the Loan or environmental claims. Leverage is moderate: the resulting loan-to-capitalization ratio is approximately 50.52%, based on the maximum offering amount and the loan balance. The Manager also established an Amortization Reserve, funded from operating income over the first three years, to help support future amortization payments once the interest-only period ends.
Sponsor track record and management: The offering is sponsored by NexPoint, a Dallas, Texas-based alternative investment platform operating since 2012 that manages a broad range of real estate and credit strategies. The PPM describes NexPoint and its affiliates as an investment platform with approximately $19 billion in assets (an affiliated figure of roughly $14.6 billion also appears in the document) across externally managed, publicly traded REITs, business development companies, closed-end and interval funds, and private real estate offerings, spanning multifamily, single-family rental, self-storage, hospitality, real estate finance, and life sciences. The Trust is managed by NREA LS III Manager, LLC, an affiliate of the Sponsor, which also serves as Signatory Trustee and holds the sole power to determine when to sell or otherwise transfer the Property, consistent with the trustee powers permitted under Revenue Ruling 2004-86. An affiliated Asset Manager provides ongoing asset-management services under a graduated fee schedule tied to the $57,750,000 purchase price.
Tax treatment and exit optionality: The Interests are intended to qualify as direct ownership of real property for federal income tax purposes, allowing accredited investors to use the offering to complete a Section 1031 like-kind exchange and defer capital gains, with purchasers deemed to assume their pro rata share of the assumed Loan. The DST is structured to satisfy the constraints of Revenue Ruling 2004-86. On exit, the Sponsor (through an affiliated "Exchange Entity") holds an Exchange Right allowing it to require beneficial owners to exchange their Interests for units in the Exchange Entity or to have their Interests purchased for cash, providing a potential Section 721-style path to continued tax deferral. Separately, after the second anniversary of the acquisition, the Sponsor may (but is not obligated to) extend a Periodic Purchase Offer to buy some or all of an owner's Interests. Distributions are projected to be paid monthly, beginning at approximately 4.01% to 4.10% per annum and escalating toward roughly 4.18% over the projected hold, though distributions are not guaranteed.
Analysis of NexPoint Life Sciences III DST
Insights
Analytical take: NexPoint Life Sciences III DST is best understood as a long-duration, single-tenant net-lease bond-like investment wrapped in a 1031-eligible DST, with the equity return driven mostly by Kindeva's rent and any residual value at exit rather than by active value-add. For a 1031 exchanger, the fit is strongest for an accredited investor with meaningful embedded gain who prioritizes deferral, passivity, and predictable monthly income over control and liquidity, and who can hold through the projected ~13-year horizon reflected in the master-lease rent schedule (Year 1 base rent of about $3,467,104 stepping to roughly $3.8 million before a partial final year). The risk/return profile is moderate but asymmetric: projected distributions of roughly 4.01%-4.18% per year are modest for the illiquidity taken, and the upside depends on cap-rate stability and residual value, while the downside is concentrated in a single tenant and a single asset. Key items to watch. First, tenant health: Kindeva's credit, its continued use of the building as headquarters and primary manufacturing, and whether it exercises its five-year extension options as 2036 approaches are the central determinants of both income and exit value. Second, the master-tenant structure: rent flows through a thinly capitalized affiliated Master Tenant supported by a $1,900,000 Demand Note, and the Sponsor's ability to defer master rent means headline distribution rates may not equal cash actually received in a stress scenario. Third, the 2029 rate reset: with the loan converting from interest-only to amortizing and repricing to a three-year Treasury plus 2.00% (capped at 6.25%), later-year cash flow and refinancing/exit timing are sensitive to the rate environment. Fourth, the load spread: an approximately 9.35% offering load plus a 3.0% disposition fee and ongoing asset-management fees mean the Property must appreciate simply to return invested capital, so entry basis (a $57,750,000 price versus a $59,000,000 appraisal) and exit cap rate matter enormously. Fifth, exit path: the Sponsor's Exchange Right offers a potential Section 721 roll-up for continued deferral, but it is the Sponsor's option, not the investor's, and terms are not fixed in advance. Compared with a diversified net-lease DST, this offering trades diversification for the quality and stickiness of a mission-critical life-sciences facility; investors are effectively underwriting Kindeva and the durability of specialized life-sciences demand in the Minneapolis MSA. It is an analytical, not promotional, fit for exchangers who want a single, high-conviction, hard-to-replicate asset and who understand that the DST form removes their ability to adapt the investment if circumstances change.
Advantages
Advantages specific to this offering: (1) A newly built (2021), purpose-built, 137,811-square-foot life-sciences facility that serves as the corporate headquarters and primary manufacturing site for Kindeva, a global CDMO backed by Altaris Capital Partners, giving the asset high switching costs and a strong barrier to vacate. (2) 100% occupancy under a long-dated lease with a 15-year initial term running to September 30, 2036 and three five-year extension options, providing extended contractual income visibility and built-in rent escalations. (3) Passive, turnkey 1031-exchange eligibility: accredited investors can defer capital gains, satisfy debt-replacement requirements through their pro rata share of the assumed $31,300,000 loan, and avoid active management via the absolute-net master-lease structure. (4) Moderate, non-recourse leverage at roughly 50.52% loan-to-capitalization, with no personal guarantees and interest-only payments for the first three years to support early cash flow. (5) A pricing anchor: a $57,750,000 purchase price against a $59,000,000 "as is" appraisal. (6) An institutional Sponsor in NexPoint, a Dallas-based platform with roughly $19 billion in assets and multiple public REITs. (7) Exit optionality through the Sponsor's Exchange Right (a potential Section 721-style roll-up into an affiliated entity for continued deferral) and a discretionary Periodic Purchase Offer after year two. (8) Monthly projected distributions beginning around 4.01%-4.10% per annum with modeled escalation toward approximately 4.18%.
Concerns
Honest, PPM-sourced risks: (1) Illiquidity: there is no public market for the Interests, transfer is restricted, and investors must hold for an indefinite period; a sale of Interests may yield less than a pro rata share of a whole-property sale. (2) No control: beneficial owners have no voting rights and cannot manage the Property; the affiliated Manager holds sole authority over sale and transfer decisions, subject to the DST's Revenue Ruling 2004-86 restrictions that prohibit the Trust from renegotiating leases or refinancing debt. (3) Single-asset, single-tenant concentration: the Trust owns one building fully dependent on Kindeva, with no diversification by asset type or geography; a Tenant default, downsizing, or non-renewal would sharply impair income. (4) Master Tenant credit risk: the Master Tenant is a newly formed, thinly capitalized affiliate whose rent obligations are supported chiefly by a $1,900,000 Demand Note from its parent, and the Sponsor may elect to defer master rent, reducing distributions. (5) Leverage and interest-rate reset: the $31,300,000 non-recourse loan resets in late 2029 to a three-year Treasury yield plus 2.00% (floor 4.25%, cap 6.25%), amortization begins after the interest-only period, and a default could lead to foreclosure and total loss. (6) Fees and load: purchasers pay roughly 9.35% in selling commissions and offering expenses (about $2,866,827 of the maximum raise), plus an ongoing asset-management fee and a 3.0% disposition fee, so total capitalization exceeds the property's appraised value. (7) Springing LLC / tax risk: if the Trust faces distress, the Manager may transfer assets to a "Springing LLC," which can terminate 1031 treatment going forward and may not qualify for tax deferral under Section 721. (8) Distributions are not guaranteed and may be funded from reserves; the Interests are unregistered, and 1031 qualification depends on tax assumptions the Sponsor does not warrant.
NexPoint Life Sciences III DST — Complete Offering Data
Offering & Structure
Investment NameNexPoint Life Sciences III DST
SponsorNexPoint
StructureDelaware Statutory Trust (DST)
Offering Type506(c)
StatusLimited Availability
Last Updated2026-07-31
Size & Availability
Total Offering$61,961,253
Equity$30,661,253
Debt$31,300,000
Available Equity$2,500,000 (8.2% of equity)
Minimum Investment$100,000
Total Load9.35%
Property
Property TypeLife Sciences
StrategyCore
LocationMN
Market TierTier 1
Income & Projections
Average Yield4.07%
Projected Yields (Y1–Y10)Y1 4.18% · Y2 4.03% · Y3 4.01% · Y4 4.04% · Y5 4.06% · Y6 4.06% · Y7 4.07% · Y8 4.07% · Y9 4.10%
Tax-Adjusted Yield11.02%
Cap Rate Equivalent8.32%
Financing
In-Place LTV50.52% LTV
LenderWings Financial Credit Union
Loan TypeFixed
Interest Rate4.50% (Fixed)
Loan Term10 years
I/O Period3 years
Amortization25 years
Y1 DSCR2.56x
Exit
Estimated Hold Period9 years
721 Exchange ExitOptional
Benchmarks (vs sector median)
Avg. Income4.07% vs 4.07% market — Meets Average
Growth0.00% vs 0.00% market
Peak4.18% vs 4.18% market — Meets Average
Every data point Baker 1031 tracks for this offering, in one place. Figures are drawn from the offering’s private placement memorandum and sponsor materials unless noted, are summaries for convenience only, and are qualified in their entirety by the PPM. Tap the ⓘ icon next to any label for what it means and how it is calculated.
